Stock VRDN VIRIDIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Viridian Therapeutics, Inc.

Equities

VRDN

US92790C1045

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
12.19 USD +0.66% Intraday chart for Viridian Therapeutics, Inc. -9.90% -44.03%
May. 16 Transcript : Viridian Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 04:35 PM
May. 09 Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
AQ
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
BU
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
BU
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
VIRIDIAN Kaskela Law LLC Announces Investigation of Viridian Therapeutics, Inc. (VRDN) and Encourages Investors to Contact the Firm
PR
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
BU
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
BU
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
AQ
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
BU
Viridian Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4)
AQ
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
BU
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
BU
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
BU
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
BU
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
BU
Viridian Therapeutics : Subcutaneous IGF-1R program selection Presentation
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VRDN Stock
  4. News Viridian Therapeutics, Inc.
  5. Press Releases